• Tiziana Life Sciences reported its Phase 2a INFORM-MS trial met both primary endpoints in non-active secondary progressive multiple sclerosis.
• Intranasal foralumab reduced brain immune-cell activation versus placebo at the lower dose; both doses improved fatigue, with favorable safety and tolerability.
• Findings aligned with longer-term expanded-access observations of disability stabilization and improvement.
• Topline results were reviewed November 9, 2026; detailed findings will be presented at an upcoming scientific meeting.
• The developer plans to discuss next steps with the FDA for a condition with no specifically indicated FDA-approved therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611091330OMX_____CNEWS_EN_GNW9873367_en) on November 09, 2026, and is solely responsible for the information contained therein.